Researchers at The University of Texas Health Science Center at San Antonio have discovered a way to delay or even block ...
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.
Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...
Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...
Salley's reason for running goes beyond the thrill of crossing the iconic Ravanel Bridge. Five years ago, her mother was ...
Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback